in patients treated withcitalopram was greater than the incidence in placebo-treated patients.The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medicalpractice where patient characteristics and other factors differ from those which prevailed in the clinical trials.